Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 4.48% is 78% below its 5-year average of 20.29%, near the low end of its 5-year range (4.48%–51.48%).
As of the fiscal period ended Tuesday, June 30, 2026. 9.48% below its 12-month average of 4.95%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 4.48%.
DEBT TO ASSETS RATIO
4.48%
DEBT TO ASSETS RATIO AVG TTM
4.95%
DEBT TO ASSETS RATIO AVG 3Y
7.33%
DEBT TO ASSETS RATIO AVG 5Y
20.29%
DEBT TO ASSETS RATIO AVG 10Y
33.38%
DEBT TO ASSETS RATIO AVG 15Y
30.75%
DEBT TO ASSETS RATIO AVG 20Y
32.06%
CURRENT VS TTM AVG
-9.48%
CURRENT VS 3Y AVG
-38.90%
CURRENT VS 5Y AVG
-77.93%
CURRENT VS 10Y AVG
-86.58%
CURRENT VS 15Y AVG
-85.44%
CURRENT VS 20Y AVG
-86.03%
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 873 covered companies
CURRENT VS SECTOR MEDIAN
+4875.59%
vs the sector median at left
Standard BioTools Inc.
Market Cap
$282.64M
Debt to Assets Ratio
4.48%
TTM Avg
4.95%
3Y Avg
7.33%
5Y Avg
20.29%
Market Cap
$281.54M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$284.31M
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$280.37M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$285.42M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$285.55M
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$288.79M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$292.59M
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$293.30M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Standard BioTools Inc. (LAB) | $282.64M | 4.48% | 4.95% | 7.33% | 20.29% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.54M | 0.02% | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $284.31M | 0.04% | N/A | N/A | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $280.37M | 0.01% | N/A | N/A | N/A |
| Sagimet Biosciences Inc. (SGMT)vs › | $285.42M | 0.01% | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.55M | 0.11% | N/A | N/A | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $288.79M | 0.03% | N/A | N/A | N/A |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $292.59M | 0.04% | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $293.30M | 0.00% | N/A | N/A | N/A |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $271.81M | 0.06% | N/A | N/A | N/A |
Debt/Assets
4.5%
Debt/Equity
0.05
Current Ratio
9.10
Interest Coverage
-3588.7x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 4.48% |
| 2026-03-31 | 4.61% |
| 2025-12-31 | 5.43% |
| 2025-09-30 | 5.08% |
| 2025-06-30 | 5.14% |
| 2025-03-31 | 5.44% |
| 2024-12-31 | 5.39% |
| 2024-09-30 | 13.13% |
| 2024-06-30 | 12.78% |
| 2024-03-31 | 11.82% |
| 2023-12-31 | 30.40% |
| 2023-09-30 | 29.39% |
| 2023-06-30 | 28.49% |
| 2023-03-31 | 27.44% |
| 2022-12-31 | 26.30% |
| 2022-09-30 | 24.85% |
| 2022-06-30 | 23.48% |
| 2022-03-31 | 51.48% |
| 2021-12-31 | 40.57% |
| 2021-09-30 | 37.24% |
| 2021-06-30 | 33.17% |
| 2021-03-31 | 30.89% |
| 2020-12-31 | 29.37% |
| 2020-09-30 | 29.55% |
| 2020-06-30 | 33.76% |
| 2020-03-31 | 32.64% |
| 2019-12-31 | 22.65% |
| 2019-09-30 | 21.04% |
| 2019-06-30 | 20.44% |
| 2019-03-31 | 20.14% |
| 2018-12-31 | 56.66% |
| 2018-09-30 | 67.12% |
| 2018-06-30 | 64.36% |
| 2018-03-31 | 60.87% |
| 2017-12-31 | 67.94% |
| 2017-09-30 | 66.84% |
| 2017-06-30 | 70.00% |
| 2017-03-31 | 66.68% |
| 2016-12-31 | 63.63% |
| 2016-09-30 | 60.82% |
| 2016-06-30 | 56.96% |
| 2016-03-31 | 54.94% |
| 2015-12-31 | 52.74% |
| 2015-09-30 | 51.69% |
| 2015-06-30 | 50.26% |
| 2015-03-31 | 49.49% |
| 2014-12-31 | 47.96% |
| 2014-09-30 | 47.61% |
| 2014-06-30 | 46.76% |
| 2014-03-31 | 45.97% |
| 2013-12-31 | 0.00% |
| 2013-09-30 | 0.00% |
| 2013-06-30 | 0.00% |
| 2013-03-31 | 0.00% |
| 2012-12-31 | 0.00% |
| 2012-09-30 | 1.60% |
| 2012-06-30 | 7.24% |
| 2012-03-31 | 8.98% |
| 2011-12-31 | 12.78% |
| 2011-09-30 | 14.03% |
| 2011-06-30 | 15.18% |
| 2011-03-31 | 15.14% |
| 2010-12-31 | 71.87% |
| 2010-09-30 | 66.14% |
| 2009-12-31 | 44.98% |
| 2008-12-31 | 47.02% |
| 2008-06-30 | 33.33% |
| 2007-12-31 | 26.21% |
